# A Study of LY2963016 Compared to LANTUS® in Adult Participants With Type 2 Diabetes Mellitus

> **NCT02302716** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 493 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** LY2963016
- **DRUG:** LANTUS®
- **DRUG:** Oral Antihyperglycemic Medication

## Key facts

- **NCT ID:** NCT02302716
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12
- **Primary completion:** 2016-07
- **Final completion:** 2016-07
- **Target enrollment:** 493 (ACTUAL)
- **Last updated:** 2017-10-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02302716

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02302716, "A Study of LY2963016 Compared to LANTUS® in Adult Participants With Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02302716. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*